DexCom (DXCM) 2025 — Grade A: Cleanest MedTech, FCF +71%, Zero Red Flags

Grade: A — Strong Financial Health

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (filed Feb 12, 2026) + Yahoo Finance

Auditor: Deloitte & Touche LLP — Clean opinion (unqualified)

One-line verdict: DexCom should not be flagged for elimination. Zero red flags across 17 checks, M-Score deeply clean at -2.71, $1.1 billion in free cash flow (FCF/NI of 1.29), net cash position on the balance sheet, and 60.1% gross margins in a high-growth medical device business. Every earnings dollar is backed by cash. The only material risk in the 10-K is regulatory: CMS is subjecting continuous glucose monitors to competitive bidding starting in 2027-2028, which will compress Medicare reimbursement rates. That is a business risk, not an accounting red flag.

The Business: Dominant in Continuous Glucose Monitoring

DexCom is the leading manufacturer of continuous glucose monitoring (CGM) systems for diabetes management. The company's G7 and G7 15 Day sensors represent the latest generation of its technology. In August 2024, DexCom launched Stelo, the first over-the-counter glucose biosensor in the U.S., targeting adults with prediabetes and Type 2 diabetes who do not use insulin.

The business model is a classic razor-and-blade: reusable transmitters and receivers generate recurring revenue from disposable sensor sales. The 10-K notes the company added "approximately 600,000-700,000 net customers, excluding Stelo customers, to our worldwide customer base in 2025."

Profitability: Accelerating Growth Engine

Revenue grew 16% to $4.66 billion, "primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base." The 10-K breaks this down: U.S. revenue was $3.33 billion (+15.4%) and international revenue was $1.33 billion (+16.1%).

Operating income surged 52% from $600 million to $912 million. The operating margin expanded from 14.9% to 19.6% because SG&A spending grew only 0.4% on a $629 million revenue increase — extraordinary operating leverage. The 10-K notes SG&A "increased primarily due to $83.7 million in higher compensation and related costs" but was "offset by $87.2 million in lower legal expense primarily related to a patent infringement lawsuit that was settled in December 2024."

Gross margin declined 40 basis points to 60.1%, driven by "inefficiencies associated with ensuring supply availability, build configurations that lowered production yield, and total replacement costs." While the four-year declining trend in gross margin (from 64.7% to 60.1%) bears monitoring, 60% gross margins remain exceptional for a medical device company manufacturing at scale.

Cash Flow: Exceptional and Accelerating

CFFO/NI of 1.72 means that for every dollar of reported earnings, DexCom generates $1.72 in operating cash. This is one of the strongest cash conversion ratios in our coverage universe.

FCF nearly doubled from $631 million to $1.08 billion. FCF/NI of 1.29 means free cash flow exceeds net income — the company is generating more cash than it reports in earnings. This is the hallmark of a high-quality earnings stream.

Operating cash flow grew 46% year-over-year, compared to 16% revenue growth and 45% net income growth. Cash generation is accelerating faster than the P&L.

Balance Sheet: Fortress

DexCom has a net cash balance sheet. The $1.4 billion in debt consists of senior convertible notes (the 2028 Notes from the May 2023 offering), which carry minimal cash interest expense. Interest coverage of 49.8x means interest is irrelevant to the P&L.

Goodwill of $24 million and intangibles of $71 million represent just 3% of equity — the cleanest balance sheet in MedTech. There is no acquisition impairment risk.

The 10-K states: "Our cash, cash equivalents and short-term marketable securities totaled $2.00 billion as of December 31, 2025. None of those funds were restricted and $1.66 billion (approximately 83%) of those funds were located in the United States."

The 18-Point Screening

Revenue Quality

The DSO of 95 days is elevated for a product company but explainable: DexCom sells through distributors and pharmacies with insurance reimbursement cycles, and the 10-K notes the company estimates pharmacy rebates with "a time delay between the recording of the pharmacy rebate and its ultimate settlement, an interval that generally ranges from 30 to 90 days, but can last up to one year."

A3 is particularly clean: CFFO grew nearly 3x faster than revenue, meaning the cash generation engine is accelerating.

Expense Quality

Inventory and COGS growing in lock-step (15.9% vs 16.6%) is a clean signal — no inventory build-up. CapEx growing only 1.3% while revenue grew 15.6% indicates the company's manufacturing infrastructure is scaling efficiently.

Cash Flow Quality

Every cash flow check passes with strong results. The accruals ratio of -9.5% is one of the lowest (most conservative) in our coverage universe — this means DexCom's reported earnings significantly understate its cash earnings.

Balance Sheet

Acquisition Risk

M-Score

All eight M-Score components are within clean bounds. SGAI of 0.869 reflects the SG&A operating leverage. TATA of -0.095 confirms the negative accruals signal — cash earnings exceed reported earnings.

Key Risks from the 10-K

1. Medicare Competitive Bidding — The Biggest Threat

The most significant risk in the 10-K is the CMS decision to subject CGMs to the DMEPOS competitive bidding program. The 10-K provides extensive detail: "In late 2025, CMS extended the DMEPOS competitive bidding program to include our CGMs and receivers, with contracting beginning in 2027 and payment changes taking effect in 2028."

The pricing mechanism is particularly concerning: "CMS is changing the pricing under the RID CBA by setting a single payment amount for covered items at the 75th percentile of the winning bids, rather than using the maximum winning bid." Combined with the shift to monthly rental payments (bundling receiver cost over 60 months), "we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028."

This is a material revenue risk for a company where third-party reimbursement is the primary payment mechanism.

2. Medicaid and ACA Coverage Reductions

The One Big Beautiful Bill Act signed in July 2025 reduces Medicaid spending by an estimated $1 trillion and may increase uninsured populations by 11.8 million. The 10-K warns: "Decreased federal funding and stricter eligibility requirements may result in more restrictive Medicaid programs at the state level and fewer individuals eligible for coverage, which could have an adverse impact on the number of individuals who seek to use our products."

3. Gross Margin Erosion

While still exceptional at 60.1%, gross margin has declined from 64.7% in FY2022 to 60.1% in FY2025 — a loss of 4.6 percentage points in three years. The 10-K attributes the FY2025 decline to "inefficiencies associated with ensuring supply availability, build configurations that lowered production yield, and total replacement costs." If competitive bidding compresses reimbursement while manufacturing costs continue to rise, the margin squeeze could accelerate.

4. Increasing Competition

The 10-K notes that CMS's December 2021 rule "expanded coverage of CGMs to include competing devices, which may continue to have a negative impact on our sales as a result of increased market competition." Abbott's FreeStyle Libre and other CGM entrants are gaining share, particularly in international markets and the growing Type 2 diabetes segment.

5. Pharmacy Rebate Estimation

The 10-K identifies pharmacy rebates as the "most significant component of variable consideration estimates" and notes that a 1% change in estimated products subject to rebate would change revenue by approximately $50.1 million. While historical adjustments have been "less than 1% of revenue," this estimation risk grows as pharmacy channel revenue increases.

Summary

Grade: A. Should not be flagged for elimination.

DexCom is one of the cleanest financial profiles in our coverage universe: zero red flags, zero watch items across 17 checks, M-Score deeply clean at -2.71, accruals ratio of -9.5% (earnings understated vs cash), FCF/NI of 1.29 (free cash exceeds reported earnings), net cash balance sheet, 3% goodwill-to-equity ratio, and interest coverage of 49.8x.

The company is growing revenue at 16%, growing operating income at 52%, growing FCF at 71%, and doing all of this with declining capital intensity (CapEx grew only 1.3%). This is the financial profile of a high-quality growth business with massive operating leverage.

The risks are entirely external: CMS competitive bidding will compress Medicare reimbursement starting 2028, Medicaid changes may reduce coverage, and competition from Abbott and others is intensifying. But none of these show up as red flags in the financial statements — the books are pristine.

**Disclaimer**: This report is based on DexCom's FY2025 10-K (SEC EDGAR, filed Feb 12, 2026) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K + Yahoo Finance

Auditor: Deloitte & Touche LLP (Unqualified opinion)